ONCODES.PREC.MED. EO-34 (ZR8) — Working Capital to Net Assets Ratio
ONCODES.PREC.MED. EO-34 (ZR8) has a Working Capital to Net Assets ratio of -1178.1% as of December 2024. Working capital of €5.06 Million (current assets of €8.67 Million minus current liabilities of €3.61 Million) is measured against net assets of €-429.39K. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is ONCODES.PREC.MED. EO-34's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ONCODES.PREC.MED. EO-34 Working Capital to Net Assets (2021–2024)
This chart shows how ONCODES.PREC.MED. EO-34's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at -1178.1%, reflecting working capital of €5.06 Million against net assets of €-429.39K EUR. Check ZR8 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for ONCODES.PREC.MED. EO-34 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for ONCODES.PREC.MED. EO-34 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see ZR8 market cap overview.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -1178.1% | €5.06 Million | €-429.39K | €8.67 Million | €3.61 Million | ▼ -1456.9 pp |
| 2023 | 278.8% | €10.29 Million | €3.69 Million | €14.40 Million | €4.11 Million | ▲ +173.2 pp |
| 2022 | 105.6% | €12.45 Million | €11.78 Million | €16.41 Million | €3.96 Million | ▼ -21.0 pp |
| 2021 | 126.6% | €5.32 Million | €4.20 Million | €6.53 Million | €1.21 Million | — |